Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This research discusses the parallel clinical development of ritlecitinib, an oral Janus kinase 3/tyrosine kinase inhibitor, for treating conditions such as alopecia areata, vitiligo, ulcerative colitis, Crohn's disease, and rheumatoid arthritis. Results are not reported in the abstract.

This article describes viDA Therapeutics Inc.'s focus on developing new drugs for age-related conditions using their proprietary granzyme-based approach but reports no clinical outcomes, primarily discussing their funding and business strategy.

In this retrospective review, tofacitinib treatment was associated with clinically significant hair regrowth in most adolescent patients with alopecia areata, though limitations suggest further studies are needed to confirm these findings.

This article reviews historical reports of skin changes, such as pseudoacanthosis nigricans, associated with cholesterol-lowering drugs like triparanol and nicotinic acid, but presents no new clinical findings.

This article offers strategies for managing acne effectively and safely, emphasizing treatment optimization, patient tailoring, and addressing antimicrobial resistance, but reports no new clinical results.

In this report, two women treated with alitretinoin experienced persistent curling of their previously straight hair, suggesting a likely causal link between the medication and hair texture changes.

In this study, the vitamin D analogues 1 alpha,25-dihydroxy-vitamin D3 and calcipotriol were found to thin the living cell layer and affect differentiation marker expression in organotypic cultures of human outer root sheath cells.

This case report and literature review highlights an unusual acne-like presentation of chronic cutaneous lupus erythematosus that doesn't improve with standard acne treatments, emphasizing the importance of considering CCLE in atypical acneiform eruptions.

This study found that baricitinib can counteract the cytokine-driven reduction of the enzyme PADI1 in human keratinocytes, which may help improve skin barrier function in atopic dermatitis by enabling epidermal differentiation.

This study found that hair rejuvenation therapies and patient comorbidities, such as diabetes mellitus, were significantly associated with adverse drug reactions in cosmetic treatment recipients.

This review discusses the application and potential of baricitinib, a JAK1/2 inhibitor, for treating dermatological diseases like alopecia areata and reports no new clinical results.

This study observed that minimal doses of the arotinoid RO 13-6298 successfully treated two cases of severe psoriasis and psoriatic arthritis unresponsive to traditional therapies, despite some side effects.

This study found that valproic acid may interfere with the leucine metabolic pathway by inhibiting 3-methylcrotonyl-CoA carboxylase and biotinidase, which could contribute to side effects like skin rash and hair loss in patients.

AI-09 is safe, effective, and reduces wrinkles for up to 6 months.

This article reviews the use of alitretinoin for corticosteroid-refractory chronic hand eczema and explores its potential therapeutic benefits in other skin conditions, but reports no clinical results.

In this study, topical tacrolimus 0.03% cream showed good to excellent response in treating alopecia areata in 70% of participants, with no cutaneous or systemic side effects observed.

In this case study, alopecia was observed as a possible side effect in a patient taking oral acyclovir for herpetic keratouveitis, which resolved after discontinuing the medication.

This review discusses the adverse effects of dermatological drugs, topical agents, and cosmetics, reporting no new clinical findings; the authors highlight several concerns such as cancer risk from hair dyes and systemic absorption issues with minoxidil.

In this study, tofacitinib was found to be a promising treatment for adolescents with alopecia areata, showing significant hair regrowth in most patients with mild adverse effects, despite limitations like small sample size and lack of control group.

CTP-543 is generally safe for treating alopecia areata.

In this study, researchers analyzed adverse events linked to avacopan using FDA data, finding no high-priority safety concerns but identifying five potential new adverse events, including alopecia, primarily among American patients, and noting a higher risk of liver dysfunction in Japanese patients.

This article describes Revifol, a nutritional supplement claimed to improve hair health, but it presents no new experimental findings or clinical results.

This study found that calcitriol protects keratinocytes from the cell detachment and apoptosis caused by captopril exposure.

This study found that tofacitinib is an effective and more tolerable treatment than systemic corticosteroids for moderate-to-severe alopecia areata, and its combination with corticosteroids may offer improved efficacy.

In this study, JAK inhibitors for treating alopecia areata and atopic dermatitis were generally well tolerated in a real-world setting, with most adverse events being mild or moderate and rare serious cases resembling the general population incidence.

This study found that combining oral isotretinoin with topical treatments was more effective than topical treatments alone for improving frontal fibrosing alopecia symptoms, despite some side effects.

This study found that the antiviral drug daclatasvir significantly improved fibrosis and quality of life in a mouse model of recessive dystrophic epidermolysis bullosa, suggesting potential for treating this and other fibrotic diseases.

This case report describes successful treatment of folliculitis decalvans in a 41-year-old woman using oral fusidic acid, leading to clinical improvement and no recurrences after six months.

In this randomized clinical trial, the authors reported that after 12 weeks, 5% dapsone gel was more effective than 1% clindamycin phosphate gel in treating mild to moderate acne vulgaris, showing efficacy in 78.2% of patients compared to 52.7% with clindamycin.